Dysbiotic Co-Factors in Cervical Cancer. How the Microbiome Influences the Development of Cervical Intraepithelial Neoplasia (CIN).
CIN lesion
HPV infection
vaginal microbiome
Journal
Geburtshilfe und Frauenheilkunde
ISSN: 0016-5751
Titre abrégé: Geburtshilfe Frauenheilkd
Pays: Germany
ID NLM: 0370732
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
09
12
2022
accepted:
20
02
2023
medline:
17
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
Human papillomavirus (HPV) infection is a necessary but not sufficient condition for the development of cervical cancer. The dysbiotic shift in the cervicovaginal microbiome appears to be a major co-factor in carcinogenesis. New analytical methods, such as next-generation sequencing (NGS), can be used to detect all of the vaginal microorganisms present and therefore identify individual therapeutic options. The relationship of bacterial vaginosis and carcinogenesis, as well as possible indications for the use of microbiome analysis, will be discussed.
Identifiants
pubmed: 37588255
doi: 10.1055/a-2044-0162
pii: GebFra-2022-12-1918-U
pmc: PMC10427202
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1017-1021Informations de copyright
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare that they have no conflict of interest.
Références
Am J Reprod Immunol. 2014 Jun;71(6):555-63
pubmed: 24832618
Microb Ecol Health Dis. 2017 Jan 01;28(1):1357417
pubmed: 28959181
Trends Microbiol. 2017 Mar;25(3):182-191
pubmed: 27914761
N Engl J Med. 2020 May 14;382(20):1906-1915
pubmed: 32402161
Sci Rep. 2017 Aug 31;7(1):10200
pubmed: 28860468
Infect Agent Cancer. 2019 Oct 26;14:29
pubmed: 31673281
Anaerobe. 2005 Jun;11(3):145-53
pubmed: 16701545
Front Oncol. 2021 Jul 28;11:722639
pubmed: 34395294
Eur J Cancer Prev. 2013 Jan;22(1):46-51
pubmed: 22706167
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Papillomavirus Res. 2016 Dec;2:85-88
pubmed: 29074190
PLoS Pathog. 2020 Jun 4;16(6):e1008524
pubmed: 32497113
mBio. 2015 Oct 06;6(5):e01084-15
pubmed: 26443453
Cancer Prev Res (Phila). 2016 May;9(5):357-66
pubmed: 26935422
PLoS One. 2012;7(10):e45201
pubmed: 23056195
Microbiome. 2020 Nov 23;8(1):166
pubmed: 33228810
Microbiome. 2016 Nov 1;4(1):58
pubmed: 27802830
mBio. 2013 Aug 06;4(4):
pubmed: 23919998
J Infect Dis. 2014 Dec 1;210(11):1723-33
pubmed: 24943724
Eur Rev Med Pharmacol Sci. 2022 Jan;26(1):90-98
pubmed: 35049024
J Infect Dis. 2007 Jun 1;195(11):1582-9
pubmed: 17471427
Nat Methods. 2022 Jul;19(7):845-853
pubmed: 35773532
J Infect Dis. 2019 Sep 13;220(8):1243-1254
pubmed: 31242505
Sci Rep. 2015 Nov 17;5:16865
pubmed: 26574055
J Ovarian Res. 2020 Jun 11;13(1):68
pubmed: 32527332
Antiviral Res. 2007 Sep;75(3):258-65
pubmed: 17481742
PLoS Pathog. 2020 Mar 26;16(3):e1008376
pubmed: 32214382
N Engl J Med. 2018 Dec 6;379(23):2246-2254
pubmed: 30575452
Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):139-180
pubmed: 35169387
Int J Gynaecol Obstet. 1992 Mar;37(3):185-91
pubmed: 1351005